Skip to main content
Premium Trial:

Request an Annual Quote

... And Shares Climb 5 Percent After Firm Announces MassArray Add-On Launch

NEW YORK, March 16 (GenomeWeb News) - Shares of Sequenom were up 5 percent, or $.04, at $.76 in afternoon trading after the company launched two new products for the MassARRAY system.

 

The EpiTYPER assay for DNA methylation marker research and the QGE iPLEX multiplex assay for gene expression are commercially available and will be presented at the American Association of Cancer Research annual conference in April, said the company in a statement.

 

Price information was not released.

 

"With the launch of these new products, we are delivering on our product goals for the first quarter of 2006," said Harry Stylli, president and CEO of Sequenom.

The Scan

Study Tracks Off-Target Gene Edits Linked to Epigenetic Features

Using machine learning, researchers characterize in BMC Genomics the potential off-target effects of 19 computed or experimentally determined epigenetic features during CRISPR-Cas9 editing.

Coronary Artery Disease Risk Loci, Candidate Genes Identified in GWAS Meta-Analysis

A GWAS in Nature Genetics of nearly 1.4 million coronary artery disease cases and controls focused in on more than 200 candidate causal genes, including the cell motility-related myosin gene MYO9B.

Multiple Sclerosis Contributors Found in Proteome-Wide Association Study

With a combination of genome-wide association and brain proteome data, researchers in the Annals of Clinical and Translational Neurology tracked down dozens of potential multiple sclerosis risk proteins.

Quality Improvement Study Compares Molecular Tumor Boards, Central Consensus Recommendations

With 50 simulated cancer cases, researchers in JAMA Network Open compared molecular tumor board recommendations with central consensus plans at a dozen centers in Japan.